ENDO INTERNATIONAL for ENDO INTERNATIONAL

Health Issues HCR

Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 483 (114th), H.R. 6 (114th), H.R. 5748 (114th), H.R. 5046 (114th), H.R. 471 (114th), S. 524 (114th), S. 2948 (114th), H.R. 4641 (114th)

Taxation/Internal Revenue Code TAX

Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 160 (114th)

Copyright/Patent/Trademark CPT

Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 9 (114th), S. 1137 (114th)